Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharma Mar SA ( (ES:PHM) ) has issued an update.
Grupo PharmaMar reported a robust first quarter of 2026, with total revenues up 10% to €42.9 million and recurring revenues rising 7% to €40.5 million, driven by strong European demand for Zepzelca and higher oncology royalties. Net profit swung to €1.5 million from a loss a year earlier, EBITDA improved to €2.7 million, and the company strengthened its balance sheet with €168.5 million in cash and reduced financial debt of €44.7 million.
Oncology royalties climbed 14% to €16.8 million, supported by Jazz Pharmaceuticals’ Zepzelca sales and sharply higher U.S. trabectedin royalties following its inclusion in NCCN guidelines. PharmaMar continued to invest heavily in R&D, particularly the phase III SaLuDo trial in leiomyosarcoma and early-stage compounds PM54 and PM534, while securing a positive EMA recommendation for Zepzelca in combination with atezolizumab as a first-line maintenance treatment for advanced-stage small cell lung cancer, underscoring its strengthening position in oncology.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR121.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Grupo PharmaMar is a Spanish biopharmaceutical company focused on oncology, specializing in the discovery and development of marine-derived anticancer drugs. Its key commercial products include Zepzelca (lurbinectedin) and Yondelis (trabectedin), with a growing royalty stream from global partners and a pipeline targeting solid tumors.
Average Trading Volume: 59,585
Technical Sentiment Signal: Buy
Current Market Cap: €1.73B
Learn more about PHM stock on TipRanks’ Stock Analysis page.